89bio Inc (ETNB)
BIOTECHNOLOGY
Last updated: Oct 30, 2025 at 5:00 PM ET
89bio Inc (ETNB) Financials: Revenue, Profit and Cash Flow
89bio reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$367.08M, operating cash flow was -$367.82M and free cash flow was -$367.84M. The quarter ended Jun 30, 2025 had revenue of $0 and net income of -$111.50M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $384.66M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Jun 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $6.00K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | -$6.00K |
| Research and development | $345.04M | $122.23M | $80.80M | $70.33M | $36.20M | $21.35M | $13.68M |
| Operating income | -$384.66M | -$151.20M | -$102.25M | -$89.74M | -$49.35M | -$26.64M | -$15.16M |
| Net income | -$367.08M | -$142.19M | -$102.03M | -$90.12M | -$49.50M | -$57.42M | -$16.18M |
| EBITDA | -$370.20M | -$138.85M | -$100.24M | -$88.03M | -$49.00M | N/A | N/A |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $21.00K | $0 | $0 | $0 | $234.00K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $21.00K | $0 | $0 | $0 | -$16.00K | $0 | $0 | $0 | -$55.00K | $0 |
| Operating income | -$115.82M | -$75.91M | -$122.00M | -$151.94M | -$53.44M | -$57.28M | -$41.21M | -$39.34M | -$42.13M | -$28.52M | -$25.36M | -$27.04M |
| Net income | -$111.50M | -$71.28M | -$118.35M | -$149.07M | -$47.97M | -$51.68M | -$40.23M | -$34.73M | -$38.39M | -$28.84M | -$24.60M | -$26.80M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded long-term debt of $35.73M by $90.33M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Total assets | $478.69M | $596.27M | $196.82M | $162.42M | $211.07M | $95.55M | $11.37M |
| Current assets | $476.45M | $593.53M | $196.08M | $161.98M | $210.20M | $95.33M | $11.32M |
| Cash and equivalents | $126.06M | $316.16M | $55.26M | $52.43M | $98.18M | $93.33M | $11.23M |
| Total liabilities | $77.90M | $59.96M | $44.99M | $36.47M | $8.11M | $5.61M | $4.35M |
| Short-term debt | N/A | N/A | N/A | $2.50M | $0 | N/A | N/A |
| Long-term debt | $35.73M | $24.80M | $20.19M | $16.90M | $0 | N/A | N/A |
| Shareholder equity | $400.79M | $536.31M | $151.83M | $125.96M | $202.96M | $89.94M | -$16.06M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $603.49M | $685.03M | $478.69M | $458.30M | $582.14M | $577.32M | $596.27M | $460.11M | $492.51M | $494.32M | $196.82M | $200.58M |
| Total liabilities | $81.75M | $79.57M | $77.90M | $80.19M | $67.22M | $66.78M | $59.96M | $49.90M | $50.52M | $48.49M | $44.99M | $48.01M |
| Cash and equivalents | $129.08M | $315.40M | $126.06M | $91.41M | $212.22M | $217.57M | $316.16M | $251.93M | $245.44M | $350.93M | $55.26M | $72.40M |
| Shareholder equity | $521.73M | $605.46M | $400.79M | $378.10M | $514.92M | $510.54M | $536.31M | $410.21M | $441.99M | $445.83M | $151.83M | $152.57M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$367.82M | -$129.19M | -$81.09M | -$76.78M | -$46.24M | -$25.46M | -$12.47M |
| Capital expenditures | $15.00K | $4.00K | $7.00K | $63.00K | $126.00K | $139.00K | $39.00K |
| Free cash flow | -$367.84M | -$129.19M | -$81.10M | -$76.84M | -$46.37M | -$25.60M | -$12.51M |
| Dividends paid | N/A | $268.00K | N/A | $19.95M | N/A | N/A | N/A |
| Share repurchases | $253.00K | $0 | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$40.86M | -$123.02M | -$33.94M | $7.16M | -$106.83M | -$139.00K | -$39.00K |
| Financing cash flow | $218.59M | $513.11M | $117.83M | $23.87M | $157.92M | $107.70M | $23.77M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$100.42M | -$71.74M | -$121.58M | -$145.36M | -$61.16M | -$39.72M | -$34.29M | -$30.36M | -$34.45M | -$30.09M | -$27.10M |
| Capital expenditures | $0 | $72.00K | $15.00K | $0 | $0 | $0 | $4.00K | $0 | $0 | $0 | $2.00K |
| Free cash flow | -$100.42M | -$71.81M | -$121.59M | -$145.36M | -$61.16M | -$39.72M | -$34.30M | -$30.36M | -$34.45M | -$30.09M | -$27.10M |
Frequently Asked Questions About ETNB
What is 89bio's annual revenue?
89bio reported revenue of $0 for the fiscal year ended Dec 31, 2024.
Is 89bio profitable?
No. 89bio reported net income of -$367.08M for the fiscal year ended Dec 31, 2024.
How much free cash flow does ETNB generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$367.82M minus capital expenditures of $15.00K produced free cash flow of -$367.84M.
How much debt does 89bio have?
The balance sheet dated Dec 31, 2024 reported long-term debt of $35.73M and cash and equivalents of $126.06M.
ETNB pages: Overview, Financials